The SHARP trial: lessons learnt; answers and more questions!

The key question in the SHARP trial was does lipid lowering therapy in chronic kidney disease (CKD) reduce the risk of atherosclerotic and vascular events and there is no doubt that the trial clearly does. Simvastatin plus ezetimibe was associated with an average 0·85 mmol/L reduction in LDL cholesterol and a 17% reduction in major atherosclerotic events… (More)